Medicamen Biotech Limited Approves Quarter Results, Announces AGM Details and Completes Fine Payments
Medicamen Biotech Limited has approved its Unaudited Financial Results (Standalone and Consolidated) for the quarter ending June 30, 2026. The company's Board of Directors also ratified the draft Annual Report and Cost Audit Report for the financial year 2025-26. Additionally, Medicamen confirmed that it has paid regulatory fines levied by both BSE Limited and National Stock Exchange of India Limited (NSE).The Unaudited Financial Results were reviewed by the Audit Committee and subsequently approved by the Board. The results for the quarter showed Total Revenue of 17,884.58 in the standalone segment.
Key financial parameters reported during the period include:
| Particulars | Standalone Q ended 30.06.2026 (Amount) |
|---|---|
| Net Sales / Income from operations | 17,884.58 |
| Total Revenue | 17,884.58 |
| Profit/Loss before Exceptional Items & Tax | -2,387.78 |
The Board also approved the draft Annual Report and Draft Cost Audit Report for the financial year 2025-26.
Governance and Shareholder Actions Planned
Medicamen Biotech Limited announced that its 33rd Annual General Meeting (AGM) will be held on Saturday, September 26, 2026, at 12:00 Noon through Video Conferencing (VC)/Other Audio-Visual Means (OAVM).The company set various timelines related to shareholder matters. The cut-off date for casting votes electronically was fixed as September 19, 2026. The voting period for shareholders is scheduled from Wednesday, September 23, 2026, and ends on Friday, September 25, 2026.
The Board further approved the closure of the Register of Members and other Transfer Books from Saturday, September 19, 2026, to Friday, September 25, 2026. This closure is related to the proposed Final Dividend set at 10 per cent, equivalent to Re. 1/- per Equity Share, pending member approval at the forthcoming Annual General Meeting.
Regulatory Non-Compliance and Fine Payment Details
The Board of Directors reviewed communications received from BSE Limited and National Stock Exchange of India Limited (NSE) concerning non-compliance matters under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.The company had faced two separate instances of penalties from the exchanges:
- BSE Fine: The Board specifically noted a notice received from BSE Limited dated May 27, 2026, regarding non-compliance with Regulation 19(1)/19(2) of the SEBI (LODR) Regulations, 2015. This involved the inclusion of an Executive Member instead of a Non-Executive Member in the Nomination and Remuneration Committee. The basic fine levied by BSE was 794,000 plus GST amounting to $16,920, totaling R1,10,920.
- NSE Fine: The Board also noted a communication from NSE regarding listing fine fees for non-compliance with applicable requirements. This involved a basic fine of 794, aggregating to 71,10,920.
The company made the payment of these fines to both exchanges on June 02, 2026. The Board directed concerned officials to take necessary corrective and compliance measures regarding these matters.
MEDICAMEQ Stock Price Movement
Shares of Medicamen Biotech Limited slipped by 1.25% to settle at ₹240.45 in the market session today. The stock traded within a tight range during the day, bottoming out at ₹232.05 and reaching a high of ₹244.54.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: